Article
Full Access
Immune intervention studies in insulin-dependent diabetes mellitus
Jay S. Skyler,
Jay S. Skyler
University of Miami School of Medicine, 1500 Northwest 12th Avenue, Suite 900, Miami, Florida 33136
Search for more papers by this authorJay S. Skyler,
Jay S. Skyler
University of Miami School of Medicine, 1500 Northwest 12th Avenue, Suite 900, Miami, Florida 33136
Search for more papers by this author
References
- 1 Nerup J, Mandrup-Poulsen T, and Molvig J: The HLA-IDDM association: implications for etiology and pathogenesis of IDDM. Diabetes/Metab Rev 3: 779–802, 1987.
- 2 Hoover ML and Capra JD: HLA and T-cell receptor genes in insulin dependent diabetes mellitus. Diabetes/Metab Rev 3: 835–856, 1987.
- 3 Segall M and Bach FH: HLA and diabetes from a T-cell perspective. Diabetes/Metab Rev 3: 803–818, 1987.
- 4 Owerbach D, Rich C, Carnegie S, and Taneja K: Molecular biology of the HLA system in insulin dependent diabetes mellitus. Diabetes/Metab Rev 3: 819–834, 1987.
- 5 Rayfield EJ and Ishimura K: Environmental factors and insulin dependent diabetes mellitus. Diabetes/Metab Rev 3: 925–957, 1987.
- 6 Barnett AH, Eff C, Leslie RDG, and Pyke DA: Diabetes in identical twins. A study of 200 pairs. Diabetologia 20: 87–93, 1981.
- 7 Eisenbarth GS: Genes, generator of diversity, glycoconjugates, and autoimmune beta-cell insufficiency in type I diabetes. Diabetes 36: 355–364, 1987.
- 8
Bosi E,
Todd I,
Purjol-Borrell R,
Buttazzo GF:
Mechanisms of autoimmunity: relevance to the pathogenesis of type 1 (insulin-dependent) diabetes mellitus.
Diabetes/Metab Rev
10:
893–924,
1987.
10.1002/dmr.5610030405 Google Scholar
- 9
Gepts W and
Veld PAI:
Islet morphologic changes.
Diabetes/Metab Rev
10:
859–872,
1987.
10.1002/dmr.5610030403 Google Scholar
- 10 Bottazzo GF, Dean BM, McNally JM, MacKay EH, Swift PGF, and Gamble DR: In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med 313: 353–360, 1985.
- 11 Foulis AK and Farquharson MA: Aberrant expression of HLA-DR antigens by insulin-containing B-cells in recent onset type I diabetes mellitus. Diabetes 35: 1215–1224, 1986.
- 12
Lernmark A,
Li S,
Baekkeskov S,
Christie M,
Michelsen B,
Ursing J,
Olsson ML, and
Sundkvist G:
Islet specific immune mechanisms.
Diabetes/Metab Rev
10:
959–980,
1987.
10.1002/dmr.5610030407 Google Scholar
- 13
Palmer JP:
Insulin autoantibodies: their role in the pathogenesis of IDDM.
Diabetes/Metab Rev
10:
1005–1015,
1987.
10.1002/dmr.5610030409 Google Scholar
- 14
Barbosa J and
Bach FH:
Cell-mediated autoimmunity in type I diabetes.
Diabetes/Metab Rev
10:
981–1004,
1987.
10.1002/dmr.5610030408 Google Scholar
- 15 Sutherland DER, Sibley R, Xu X-Z, Michael A, Srikanta S, Taub F, Najarian J, and Goetz FC: Twin-to-twin pancreas transplantation: reversal and reenactment of the pathogenesis of type I diabetes. Trans Assoc Am Phys 97: 80–87, 1984.
- 16 Sibley RK, Sutherland DER, Goetz F, and Michael AF: Recurrent diabetes mellitus in the pancreas iso- and allograft. Lab Invest 53: 132–144, 1985.
- 17 Mordes JP, Desemone J, and Rossini AA: The BB rat. Diabetes/Metab Rev 3: 725–750, 1987.
- 18 Kolb H: Mouse models of insulin dependent diabetes: low-dose streptozotocin-induced diabetes and nonobese diabetic (NOD) mice. Diabetes/Metab Rev 3: 751–778, 1987.
- 19 Eisenbarth GS, Connelly, and Soeldner JS: The “natural” history of type I diabetes. Diabetes/Metab Rev, in press.
- 20
Elliott RB,
Crossley JR,
Berryman CC, and
James AG:
Partial preservation of pancreatic beta-cell function in children with diabetes.
Lancet
ii:
1–4,
1981.
10.1016/S0140-6736(81)90249-X Google Scholar
- 21
Elliott RB,
Crossley JR,
Berryman CC, and
James AG:
Partial preservation of pancreatic beta-cell function in children with diabetes (letter).
Lancet
ii:
631–632,
1981.
10.1016/S0140-6736(81)92761-6 Google Scholar
- 22 Elliott RB, Pilcher CC, and Edgar BW: Long-term outcome of children with insulin dependent diabetes mellitus treated ab initio with prednisone. Pediat Adolesc Endocr 15: 345–349, 1986.
- 23 Najemnik C, Kritz H, Kaspar L, and Irsigler K: Remission phase—prospective study to induce or prolong remission with closed and open-loop treatment—effect of additional cortisone treatment (abstract). Diabetologia 19: 276A, 1980.
- 24 Najemnik C, Kritz H, Kaspar L, and Irsigler K: Prospective study of remission in newly manifest insulin dependent diabetics with closed and open-loop treatment, in New Approaches to Insulin Therapy, K Irsigler, KN Kunx, DR Owens, H Regal, eds., MTP Press Limited, Lancaster, 1981, pp 159–168.
- 25 Kritz H, Najemnik C, and Irsigler K: Partial preservation of pancreatic beta-cell function in children with diabetes (letter). Lancet ii: 311, 1981.
- 26 Ludvigsson J: Prednisolon in the initial treatment of IDDM in children (abstract). Acta endocrinol 247 (suppl): 43, 1982.
- 27 Ludvigsson J, Heding L, Lernmark A, and Lieden G: An attempt to break the autoimmune process at the onset of IDDM by the use of Plasmapheresis or high doses of prednisone. Bull Int Study Group Diabetes Child Adoles 6: 11–12, 1982.
- 28 Sotos JF, Romshe CA, and Zipf WB: Immunosuppressive “pulse” treatment in IDDM of recent onset (abstract). Bull Int Study Group Diabetes Child Adolesc 10: 19, 1984.
- 29 Jackson R, Dolinar R, Srikanta S, Morris MA, and Eisenbarth GS: Prednisone therapy in early type I diabetes: immunologic effects (abstract). Diabetes 31 (Suppl 2): 48A, 1982.
- 30 Rabinowe SL and Eisenbarth GS: Immunotherapy of type I (insulin-dependent) diabetes mellitus, in Immunology in Diabetes, D Andreani, U Di Mario, KF Federlin, LG Heding, eds., Kimpton Medical Publications, London, 1984, pp 171–175.
- 31 Eisenbarth GS, Srikanta S, Jackson R, Rabinowe SL, Dolinar R, Aoki T, and Morris MA: Anti-thymocyte globulin and prednisone immunotherapy of recent onset type I diabetes mellitus. Diabetes Res 2: 271–276, 1985.
- 32 Secchi A, Pontiroli AE, Falqui L, Pastore MR, Scorza R, Carenini A, Meroni PL, and Pozza G: Prednisone, indomethacin or theophylline administration and the remission phase in recent onset type I insulin dependent diabetic patients. Transpl Proc 18: 1540–1542, 1986. ,
- 33 Mistura L, Beccaria L, Meschi F, D'Arcais AF, Pellini C, Puzzovio M, and Chiumello G: Prednisone treatment in newly diagnosed type I diabetic children: I-Yr followup. Diabetes Care 10: 39–43, 1987.
- 34 Ludvigsson J, Heding L Lieden G, Marner B, and Lernmark A: Plasmapheresis in the initial treatment of insulin-dependent diabetes mellitus in children. Br Med J 286: 176–178, 1983.
- 35 Rabinovitch A, MacKay P, Ludvigsson J, and Lernmark A: A prospective analysis of islet cell cytotoxic antibodies in insulin-dependent diabetic children: transient effects of plasmapheresis. Diabetes 33: 224–228, 1984.
- 36 Marner B, Lernmark A, Ludvigsson J, MacKay P, Matsuba I, Nerup J, and Rabinovitch A: Islet cell antibodies in insulin-dependent (type I) diabetic children treated with plasmapheresis. Diabetes Res 2: 231–236, 1985.
- 37 Ludvigsson J, Heding L, Lieden G, Marner B, and Lernmark A: Long-term effect of plasmapheresis in the initial treatment of IDDM in children. Pediat Adolesc Endocr 15: 355–361, 1986.
- 38 Rand KH, Rosenbloom AL, Maclaren NK, Silverstein JH, Riley WJ, Butterworth BE, Yoon JW, Rubenstein AH, and Merigan TC: Human leukocyte interferon treatment of two children with insulin dependent diabetes. Diabetologia 21: 116–119, 1981.
- 39 Koivisto VA, Aro A, Cantell K, Haataja M, Huttunen L, Karonen SL, Mustajoki P, Pelkonen R, and Seppala P: Remissions in newly diagnosed type I (insulin dependent) diabetes mellitus: influence of interferon as an adjunct to insulin therapy. Diabetologia 27: 193–197, 1984.
- 40 Greulich B, Lander T, Standl E, Kolb H, Gerbitz K-D, Kuschak D, and Gries FA: Immune intervention trial in newly diagnosed type I (insulin-dependent) diabetes (abstract). Diabetologia 25: 158, 1983.
- 41 Greulich B, Lander T, Standl E, Kolb H, Gerbitz K-D, Bertrams J, Albert E, Kuschak D, Mehnert H, and Gries FA: Immune intervention trial in early diabetes mellitus type I: Effects of inosiplex on metabolic and immunological parameters. Pediat Adolesc Endocr 15: 350–354, 1986.
- 42 Mirouze J, Rodier M, Richard JL, Lachkar H, and Monnier L: Effect of inosiplex on remission obtained in recent acute onset diabetes (abstract), in Immunology in Diabetes 84—International Symposium Abstracts, Rome, March 15–17, 1984, p 82.
- 43 Mirouze J and Rodier M, Personal communication.
- 44 Galluzzo A, Giordano C, Caruso C, Bottazzo GF, McNally J, Donatelli M, and Bompiani GD: Methisoprinol therapy in the early phases of type I (insulin-dependent) diabetes mellitus (abstract), in Immunology in Diabetes 84—International Symposium Abstracts, Rome, March 15–17, 1984, pp 42–43.
- 45 Leslie RDG and Pyke DA: Immunosuppression of acute insulin-dependent diabetics, in Immunology of Diabetes, WJ Irvine, ed., Teviot Scientific Publications Ltd, Edinburgh, 1980, pp 345–347.
- 46
Leslie RDG,
Pyke DA, and
Denman AM:
Immunosuppressive therapy in diabetes (letter).
Lancet
i:
516,
1985.
10.1016/S0140-6736(85)92112-9 Google Scholar
- 47 Spencer KM, Dean BM, Bottazzo GF, Medbak S, and Cudworth AG: Preliminary evidence for a possible therapeutic intervention in early type I (insulin dependent) diabetes (abstract). Diabetologia 20: 474, 1982.
- 48 Eisenbarth GS, Srikanta S, Jackson R, Dolinar R, and Morris MA: Immunotherapy of recent onset type I diabetes mellitus (abstract). Clin Res 31: 500A, 1983.
- 49 Silverstein J, Riley W, Barrett D, Maclaren N, and Rosenbloom A: Immunosuppressive therapy for newly diagnosed insulin dependent diabetes mellitus with antithymocyte globulin and prednisone (abstract). Pediatr Res 71: 295A, 1983.
- 50 Harrison LC, Colman PG, Dean B, Baxter R, and Martin FIR: Increase in remission rate in newly diagnosed type I diabetic subjects treated with azathioprine. Diabetes 34: 1306–1308, 1985.
- 51 Silverstein J, Riley W, Spillar R, Buithieu M, Barbour H, Harrison D, and Alamo A: A trial of immunosuppression with imuran. Diabetes 35 (Suppl 1): 5A, 1986.
- 52 Silverstein J, Maclaren N, Riley W, Spillar R, Barbour H, Skordis N, Buithieu M, and Winter W: Prednisone and imuran treatment of insulin dependent diabetes, in The Immunology of Diabetes, MA Jaworski, GD Molnar, RV Rajotte, and B Singh, eds., Excerpta Medica International Congress Series No. 717, Amsterdam, 1986, pp 351–357.
- 53 Silverstein J, Spillar R, Maclaren N, and Decker P: Immunotherapy with steroids and imuran in IDDM: the importance of steroid induction (abstract). Diabetes 36 (suppl 1): 74A, 1987.
- 54 Moncada E, Subira ML, Cano I, and Sanchez Ibarrola A: Treatment of type I (insulin dependent) diabetic patients with immunoregulation (abstract) Diabetologia 29: 572A, 1986.
- 55 Stiller CR, Laupacis A, Dupre J, Jenner MR, Keown PA, Rodger W, and Wolfe BMJ: Cyclosporine for treatment of early type I diabetes: preliminary results (letter). N Engl J Med 308: 1226–1227, 1983.
- 56 Stiller CR, Dupre J, Gent M, Jenner MR, Keown PA, Laupacis A, Martell R, Rodger NW, von Graffenried B, and Wolfe BMJ: Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 223: 1362–1367, 1984.
- 57 Mandrup-Poulsen T, Stiller CR, Bille G, Martell R, Keown PA, Rodger NW, von Graffenried B, Nerup J, Marner B, Heinrichs D, Dupre J, Jenner MR, Wolfe B, and Binder C: Disappearance and reappearance of islet cell cytoplasmic antibodies in cyclosporin in treated insulin dependent diabetics. Lancet i: 599–602, 1985.
- 58 Rodger NW, Dupre J, Stiller CR, Gent M, Binder C, Nerup J, Behme M, von Graffenried B, Jenner MR, Keown PA, Mandrup-Poulsen T, Laupacis A, Martell R, Mazaheri R, Wolfe BM, Marner B, and Rabinovitch A: The Canadian trial with cyclosporin: effects of immunosuppression in early-onset type I diabetes mellitus. Pediatr Adolesc Endocr 15: 340–344, 1986.
- 59
Dupre J,
Stiller CR,
Gent M,
Jenner MR,
Rodger NW,
Wolfe BM,
von Graffenried B,
Heinrichs D,
Purdon C, and
Martell R:
Effects of ciclosporin on insulin secretion in recent onset type I diabetes mellitus,
in Ciclosporin in Autoimmune Diseases,
R Schindler, ed.,
Springer-Verlag, Berlin,
1985,
pp 120–127.
10.1007/978-3-642-70607-3_17 Google Scholar
- 60 Stiller CR and the London-Steno Study Group: Cyclosporine A treatment and insulin dependent diabetes mellitus—remission and relapse. Diabetologia, in press.
- 61 Dupre J for the London-Steno Study Group: Paper presented at the Juvenile Diabetes Foundation Immunosuppressive Therapy Workshop, Houston, Texas, February 9–10, 1987.
- 62 Dupre J, Stiller CR, Jenner MR, Mahan J, Keown P, Rodger NW, and Wolfe BM: Responses to nutrients in non-insulin-requiring remission of type I diabetes during administration of cyclosporin (abstract). Diabetes 36 (suppl)1: 74A, 1987.
- 63 Assan R, Debray-Sachs M, Laborie C, Chatenoud L, Feutren G, Quiniou-Debrie MC, Thomas G, and Bach JF: Metabolic and immunological effects of cyclosporin in recently diagnosed type I diabetes mellitus. Lancet 1: 67–71, 1985.
- 64 Feutren G, Sirmai J, Laborie C, Bach JF, and Assan R: Outcome of remissions in cyclosporin-A treated diabetic patients: update on an open trial in 15 subjects. Submitted for publication.
- 65 Bach JF and Assan R for the French Study Group: Paper presented at the Juvenile Diabetes Foundation Immunosuppressive Therapy Workshop, Houston, Texas, February 9–10, 1987.
- 66 Levy-Marchal C and Czernichow P: Effect of ciclosporin (CsA) administration on the early phase of overt diabetes mellitus in children, in Diabetes 1985, M Serrano-Rios and PJ Lefebvre, eds., Excerpta Medica International Congress Series No. 700, Amsterdam, 1986, pp 544–547.
- 67 Levy-Marchal C and Czernichow P: Dose relationship effect of cyclosporin A in children at the onset of type I (insulin dependent) diabetes mellitus. Diabetologia 29: 565A, 1986.
- 68 Levy-Marchal C and Czernichow P: Effect of different dosages of cyclosporin A on the early phase of overt insulin dependent diabetes mellitus (IDDM) in children. Transpl Proc 18: 1543–1544, 1986.
- 69 Feutren G, Lapoz L, Assan R, Vialettes B, Karsenty G, Vexiau P, DuRostu H, Rodier M, Sirmai J, Lallemand A, and Bach JF for the Cyclosporin/Diabetes French Study Group: Cyclosporin increases the rate and length of remissions in insulin dependent diabetes of recent onset: results of a multicentre double-blind trial. Lancet ii: 119–124, 1986.
- 70 Bach JF, Feutren G, and Boitard C: Clinical and immunological effects of cyclosporin in type I diabetes, in The Immunology of Diabetes, MA Jaworski, GD Molnar, RV Rajotte, and B Singh, eds., Excerpta Medica International Congress Series No. 717, Amsterdam, 1986, pp 337–344.
- 71 Sai P, Debray-Sachs M, Lang F, Maugendre D, Boitard C, Feutren G, and Bach JF: Decline of anti-beta-cell cellular immunity in type I diabetics treated by cyclosporin A (abstract). Diabetes 36 (Suppl 1): 74A, 1987.
- 72 Kolb H and Nerup J for the Canadian/European Diabetes Study Group: Paper presented at the Juvenile Diabetes Foundation Immunosuppressive Therapy Workshop, Houston, Texas, February 9–10, 1987.
- 73 Skyler JS for the Miami Study Group: Paper presented at the Juvenile Diabetes Foundation Immunosuppressive Therapy Workshop, Houston, Texas, February 9–10, 1987.
- 74 O'Brien D, Chase P, and Lafferty K, Personal communication.
- 75 Larson DF: Mechanism of action: antagonism of the prolactin receptor. Progr Allergy 38: 222–238, 1986.
- 76 Palestine AG, Muellenberg-Coulombre CG, Kim MK, Gelato MC, and Nussenblatt RB: Bromocriptine and low dose cyclosporine in the treatment of experimental autoimmune uveitis in the rat. J Clin Invest 79: 1078–1081, 1987.
- 77 Myers BD, Ross J, Newton L, Lutscher J, and Perlroth M: Cyclosporin-associated chronic nephropathy. N Engl J Med 311: 699–705, 1984.
- 78
Mihatsch MJ,
Thiel G, and
Ryffel B:
Ciclosporin-associated nephropathy,
in Ciclosporin in Autoimmune Diseases,
R Schindler, ed.,
Springer-Verlag, Berlin,
1985,
pp 50–58.
10.1007/978-3-642-70607-3_8 Google Scholar
- 79 Mihatsch MJ, Thiel G, and Ryffel B: Morphology of ciclosporin nephropathy. Progr Allergy 38: 447–465, 1986.
- 80 Palestine AG, Austin HA, Balow JE, Antonovych TT, Sabnis SG, Preuss HG, and Nussenblatt RB: Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med 314: 1293–1298, 1986.
- 81 Nerup J, Bendtzen K, and Mandrup-Poulsen T: A role for cyclosporin A in the treatment of insulin dependent diabetes mellitus? Diabetic Med 2: 441–446, 1985.
- 82
Usadel KH,
Teuber J,
Schmeidl R,
Schwedes U,
Bicker U, and
Herz M:
Management of type I diabetes with ciamexone (letter).
Lancet
ii:
567,
1986.
10.1016/S0140-6736(86)90128-5 Google Scholar
- 83 Cobb WE, Molitch M, and Reichlin S: Levamisole in insulin dependent diabetes mellitus (letter). N Engl J Med 303: 1065–1066, 1980.
- 84 Heinze E, Thon A, Vetter U, and Zuppinger K: Gamma-globulin therapy in 6 newly diagnosed diabetic children. Acta Paediatr Scand 74: 179–180, 1985.
- 85 Heinze E, Zuppinger K, Thon A, and Vetter U: Gamma-globulin therapy in type I diabetes mellitus. Pediat Adolesc Endocr 15: 362–370, 1986.
- 86 Pozzilli P, Ghirlanda G, Manna R, Alfano G, Greco AV, and Andreani D: White cells transfusion in recent onset type I diabetes. Diabetes Res 3: 273–276, 1986.
- 87 Cavanaugh J, Chopek M, Binimelis J, Codina M, Eckhardt J, and Barbosa J: Adoptive immunotherapy of early type I diabetes with allogeneic white blood cell transfusions. Reported at Edmonton meeting, June 1986 (abstract). Immunol Diabetes 3: 13, 1986.
- 88 Takahashi H, Ozazaki H, Terasaki PL, Iwaki Y, Kinukawa T, Taguchi Y, Chia D, Hardiwidjaja S, Miura K, Ishizaka M, and Billing R: Reversal of transplant rejection by monoclonal antiblast antibody. Lancet 2: 1155–1158, 1983.
- 89 Ortho Multicenter Transplant Study Group: A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 313: 337–342, 1985.
- 90 Kirkman RL, Araujo JL, Busch GJ, Carpenter CB, Milford EL, Reinherz EL, Schlossman SF, Strom TB, and Tilney NL: Treatment of acute renal allograft rejection with monoclonal anti-T12 antibody. Transplantation 36: 620–626, 1983.
- 91 Chatenoud L, Baudrihaye MF, Chkoff N, Kreis H, and Bach JF: Immunological follow-up of renal allograft recipients treated prophylactically by OKT3 alone. Transpl Proc 15: 643–645, 1983.
- 92 Culler FL, O'Connor R, Kaufmann S, Jones KL, and Roth JC: Immunospecific therapy for type I diabetes mellitus. N Engl J Med 313: 695–696, 1985.
- 93 Eisenbarth GS, Personal communication.
- 94 Hanafusa T, Reported to International Diabetes Immunotherapy Group. IDIG Registry 02/02/87, issued by Kolb H, ed., Dusseldorf.
- 95 Kidson W, Personal communication.
- 96 Gorsuch AN, Spencer KM, Lister J, McNally JM, Dean BM, Bottazzo GF, and Cudworth AG: Evidence for a long prediabetic period in type I (insulin-dependent) diabetes mellitus. Lancet 2: 1363–1365, 1981.
- 97 Spencer KM, McNally J, Tarn A, and Doniach D: Appearance and disappearance of complement fixing and other islet cell antibodies amongst type I diabetes and their first degree relatives. Diabetologia 25: 195, 1983.
- 98 Srikanta S, Ganda OP, Eisenbarth GS, and Soeldner JS: Islet-cell antibodies and beta-cell function in monozygotic triplets and twins initially discordant for type I diabetes mellitus. N Eng J Med 308: 322–325, 1983.
- 99 Srikanta S, Ganda OP, Jackson RA, Gleason RE, Kaldany A, Garovoy MR, Milford EL, Carpenter CB, Soeldner JS, and Eisenbarth GS: Type I diabetes mellitus in monozygotic twins: chronic progressive beta cell dysfunction. Ann Int Med 99: 320–326, 1983.
- 100 Srikanta S and Ganda OP: Chronic progressive beta cell dysfunction in relatives of patients with type I diabetes. Diabetes 32 (suppl 1): 51A, 1983.
- 101 Levy-Marchal C, Czernichow P, Quiniou MC, Sachs M, and Bach JF: Cyclosporin administration reversed abnormalities in a prediabetic child (abstract). Diabetes 33 (suppl 1): 183A, 1984.
- 102 Ganda OP, Srikanta S, and Eisenbarth GS: ICA+ relatives of patients with type I DM: Defective insulin secretion and restoration of first phase insulin release by low dose prednisone (abstract). Diabetes 34 (suppl 1): 85A, 1985.
- 103 Eisenbarth GS, Srikanta S, Rabinowe SL, Jackson RA, Ganda OP, and Soeldner JS: Restoration of first-phase insulin secretion by daily prednisone in two islet cell antibody positive nondiabetic individuals. Trans Proc 18: 805–808, 1986.
- 104 Riley W, Hitchcock C, Alamo A, and Barbour H: Islet cell antibodies in “prediabetes”—metabolic and immunologic studies (abstract). Diabetes 34 (suppl 1): 65A, 1985.
- 105 Rubenstein AH and Pyke D: Immunosuppression in the treatment of insulin-dependent (type I) diabetes. Lancet 1: 436–437, 1987.
- 106 Assan R, Bach JF, Czernichow P, Dupre J, Stiller CR, Eisenbarth GS, Gries FA, Kolb H, Harrison LC, Lafferty K, Maclaren NK, Nerup J, Rabinovitch A, and Skyler J: Immunosuppressive drugs in diabetes (letter). Lancet 2: 1097, 1986.
